What is Radiolabelling?

Radiolabelling is a common technique employed in ADME studies by drug developers to trace the life and journey of a target molecule; how it moves around and how it breaks down. The molecule is “labelled” with a radioisotope to enable tracking of its journey via imaging technology.

Carbon-14 (or ¹⁴C) is the most favoured label choice when considering radiolabelling as it incorporates a ¹⁴C label selectively into the skeleton of the drug molecule, is detectable at very low concentrations, and its long half-life means no need for correction for radioactive decay.

Almac has extensive experience in the synthesis and analysis of stable (non radio-active) and ¹⁴C isotope labelled compounds – from drug discovery through to launch – we can label any compound at any stage, including small molecules, peptides and larger bio molecules.

Our custom radiolabelling service encompasses QC and analytical support, including method development and validation, method transfer and radiolabelling stability studies from our state-of-the-art facilities.

We are MHRA certified for ¹⁴C IMP manufacture and GMP compliance and we are fully equipped to deliver an industry-leading, cost-effective radiolabelling service.

Isotopic labelling imposes many synthetic challenges beyond those found in normal chemical synthesis. When the isotope is radioactive, this becomes even more demanding. That’s why we offer advice on the most appropriate label position for your molecule, including feasibility and metabolic stability.